Literature DB >> 21906423

Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.

Roberto Caporali1, Fabrizio Conti, Stefano Alivernini, Fabiola Atzeni, Bruno Seriolo, Maurizio Cutolo, Guido Valesini, Gianfranco Ferraccioli, Piercarlo Sarzi-Puttini, Carlo Salvarani, Serena Guiducci, Giuseppe Zampogna, Elisa Gremese, Nicolo' Pipitone, Rossana Scrivo, Serena Bugatti, Carlomaurizio Montecucco, Marco Matucci-Cerinic.   

Abstract

Given the availability of novel biologic agents for the treatment of rheumatoid arthritis (RA), various national scientific societies have developed specific recommendations in order to assist rheumatologists in prescribing these drugs. The Italian Society for Rheumatology (Società Italiana di Reumatologia, SIR) decided to update its recommendations and, to this end, a systematic literature review was carried out and the evidence derived from it was discussed and summarised as expert opinions. Levels of evidence, strength of recommendations and levels of agreement were reported. The recommendations reported are intended to help prescribing rheumatologists to optimise the use of biologic agents in patients with RA seen in everyday practice; they are not to be considered as a regulatory rule.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906423

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

Review 1.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Glucocorticoids in rheumatoid arthritis.

Authors:  Roberto Caporali; Monica Todoerti; Garifallia Sakellariou; Carlomaurizio Montecucco
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

3.  Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent.

Authors:  Ilaria Bertoldi; Georgios Filippou; Carlo Alberto Scirè; Valentina Picerno; Valentina di Sabatino; Antonella Adinolfi; Serena Pierguidi; Mauro Galeazzi; Bruno Frediani
Journal:  ISRN Rheumatol       Date:  2013-12-07

4.  Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy.

Authors:  Luca Degli Esposti; Ennio Giulio Favalli; Diego Sangiorgi; Roberta Di Turi; Giuseppina Farina; Marco Gambera; Roberto Ravasio
Journal:  Clinicoecon Outcomes Res       Date:  2016-12-21

Review 5.  Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs.

Authors:  Ennio Giulio Favalli; Serena Bugatti; Martina Biggioggero; Roberto Caporali
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411

6.  Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.

Authors:  Rossella Talotta; Fabiola Atzeni; Piercarlo Sarzi Puttini
Journal:  BMC Pharmacol Toxicol       Date:  2016-04-21       Impact factor: 2.483

7.  Effectiveness of a telemonitoring intensive strategy in early rheumatoid arthritis: comparison with the conventional management approach.

Authors:  Fausto Salaffi; Marina Carotti; Alessandro Ciapetti; Marco Di Carlo; Stefania Gasparini; Sonia Farah; Marwin Gutierrez
Journal:  BMC Musculoskelet Disord       Date:  2016-04-02       Impact factor: 2.362

8.  Drug usage analysis and health care resources consumption in naïve patients with rheumatoid arthritis.

Authors:  Diego Sangiorgi; Maurizio Benucci; Carmela Nappi; Valentina Perrone; Stefano Buda; Luca Degli Esposti
Journal:  Biologics       Date:  2015-11-06

9.  Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with Methotrexate.

Authors:  Alberto Batticciotto; Roberto Ravasio; Marta Riva; Piercarlo Sarzi-Puttini
Journal:  Adv Ther       Date:  2016-07-04       Impact factor: 3.845

10.  Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate.

Authors:  Maurizio Benucci; Roberto Ravasio; Arianna Damiani
Journal:  Clinicoecon Outcomes Res       Date:  2017-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.